Uncertainty Regarding Seasonal Influenza and Varied Patient Response Boost the Manufacturing of Flu Vaccines

Onset of novel technologies is enabling healthcare professionals to prevent infectious diseases with early intervention rather than treat patients after getting infected. However, in the present landscape, myriads of diseases persist to impact the human health, despite decades of innovative ventures. The pitfall of prevention and cure of influenza virus remains a pain point in the healthcare bracket, including service providers, and drug companies. Detection of the nature of influenza outbreaks becomes paramount for healthcare providers, as well as patients to act promptly for influenza prevention.

Although vaccines have eliminated various infectious diseases, such as smallpox, polio, and measles, the flu vaccines remain an exception due to varied effectiveness – person to person, and time to time. Infants display good response to flu vaccines, while elderly with fragile immune systems are subject to complications post flu vaccination. In addition, consumers across the globe are bombarded with timely reminders to receive vaccination from flu every year.

As per the new business intelligence report by Persistence Market Research, the flu vaccines market value reached ~US$ 1.3 Bn in 2018 and is expected to grow at a CAGR of ~7% during the stipulated period 2019-2027. The progress is majorly driven by prominence of seasonal influenza among the demographic in low- and mid-income countries (LMIC). On the contrary, the uncertain nature of the seasonal flu tends to sustain the supply-demand gap. Further, strictly hygienic manufacturing processes of flu vaccines require a significant time period due to numerous formalities – purification, quality analysis, safety controls, and packaging and regulatory approvals.

Quadrivalent Flu Vaccines – A Curb for Both Types of Influenza Virus

While trivalent vaccines protect against two influenza A types and a single B lineage, the quadrivalent vaccines protect against all the four strains of influenza virus. As such, quadrivalent flu vaccines offers enhanced prevention sans apparent increase in undesirable reactions. Quadrivalent flu vaccines are highly suitable for infants and geriatrics younger than 65 years and have been regulatory approvals to include newly chosen flu strains.

Cell-based flu vaccines (QIVc) produce better influenza-related results versus standard egg-based vaccine (QIVe) options in seasons characterized by egg-adapted changes. QIVc proves to be more efficient against QIVe in preventing influenza-like infections in individuals aging four years and above. Further, cell-based flu vaccines has been issued marketing approval by the European Commission for vaccination of individuals aging nine years and above.

Request For Report Sample: https://www.persistencemarketresearch.com/samples/28720

Sales of Flu Vaccines High in North America following Surging Incidents of Influenza

According to healthcare officials, about 7 Mn Americans have been affected by a strain of flu virus. Almost half of the demographic consulted a doctor, while 70, 000 – 84, 000 individuals have been admitted into the hospitals for influenza related infections. Further, the peak flu season in the US is December through February. Influenza is ranked among the top ten leading causes of mortality in Canada, where the infection results in above 12, 000 hospitalizations, and about 3, 500 mortalities.